Showing results (81-90 of 191) with videos related to
Sort By:
Pageof 20
Cancer Immunology, Immunotherapy : CII|August 14, 2021
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expressionHiroshi Takumida, Hidehito Horinouchi, Ken Masuda, et al.JTO Clinical and Research Reports|February 5, 2025
EGFR-Mutated Lung Adenocarcinoma With Li-Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case ReportHiroyuki Fujii, Yusuke Okuma, Makoto Hirata, et al.International Journal of Clinical Oncology|September 16, 2011
Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infectionYusuke Okuma, Naoki Yanagisawa, Yusuke Takagi, et al.Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|May 20, 2011
[A case of pulmonary MALT lymphoma with multiple nodules and ground-glass opacities]Yoshiro Nakahara, Tatsuru Okamura, Yusuke Okuma, et al.Allergology International : Official Journal of the Japanese Society of Allergology|December 26, 2013
Characteristics of the Chiba environmental challenge chamberSawako Hamasaki, Yoshitaka Okamoto, Syuji Yonekura, et al.JTO Clinical and Research Reports|May 2, 2022
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With AlectinibYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.Future Oncology (London, England)|August 14, 2023
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya, et al.Journal of Thoracic Disease|August 3, 2019
Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitorsYasuhiro Kato, Yukio Hosomi, Kageaki Watanabe, et al.Anticancer Research|January 29, 2018
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung CancerYasuhiro Kato, Jumpei Kashima, Kageaki Watanabe, et al.Respiratory Investigation|July 4, 2024
The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomasTomohiro Tanaka, Yasushi Goto, Ken Masuda, et al.Pageof 20